Navigation Links
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Date:11/16/2007

nists, including HUMIRA, have been associated in rare cases with demyelinating disease and serious allergic reactions. Rare reports of pancytopenia including aplastic anemia have been reported with TNF-blocking agents. Adverse events of the haematologic system, including medically significant cytopenia have been infrequently reported with HUMIRA.

More cases of malignancies including lymphoma have been observed among patients receiving a TNF antagonist compared with control patients in clinical trials. The size of the control group and limited duration of the controlled portions of studies precludes the ability to draw firm conclusions. Furthermore, there is an increased background lymphoma risk in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, which complicates the risk estimation. During the long-term open-label trials with HUMIRA, the overall rate of malignancies was similar to what would be expected for an age-, gender- and race-matched general population. With the current knowledge, a possible risk for the development of lymphomas or other malignancies in patients treated with a TNF antagonist cannot be excluded. All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or psoriasis patients with a history of PUVA treatment, should be examined for the presence of non-melanoma skin cancer prior to and during treatment with HUMIRA.

In clinical studies with another TNF antagonist, a higher rate of serious congestive heart failure (CHF) related adverse events including worsening CHF and new onset CHF have been reported. Cases of worsening CHF have also been reported in patients receiving HUMIRA. Physicians should exercise caution when using HUMIRA in patients who have heart failure and monitor them carefully. HUMIRA should not be used in patients with moderate or severe heart failure.

The most frequently reported adverse event (greater than or equal to 1/10 patient
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... (PRWEB) November 23, 2014 One of the ... of optics and photonics is now available to high school ... low cost. SPIE, the international society for optics and ... the complete SPIE Digital Library available to high ... , “Light-based technologies are integral to all areas of life ...
(Date:11/24/2014)... PHILADELPHIA , November 24, 2014 ... Reference Workflow, honored for dynamic leadership skills, business acumen ... scientific, technical and medical information products and services, congratulates ... Manager for Clinical Reference and Workflow, Elsevier Clinical Solutions, ... Women Worth Watching ® Awards issue of ...
(Date:11/22/2014)... Colo. (PRWEB) November 21, 2014 ... proprietary cloud based analytics and scientific testing methodologies relating ... commitment for a $750,000 line of credit from an ... extremely pleased to have secured this commitment from one ... Executive Officer of CannLabs. “This capital will help accelerate ...
(Date:11/22/2014)... 2014  The element of surprise has been a ... strike without warning. Until now, epidemiologists had nothing to ... outbreak, resulting in suboptimal responses to both the H1N1 ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... because virus gene structural changes have been found that ...
Breaking Biology Technology:SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3CannLabs Secures $750,000 Line Of Credit 2Viruses' Advantage of Surprise is Lost 2
... Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused ... cancer and autoimmune disease, today announced that Ulrik B. ... Chief Scientific Officer and Edward (Tad) J. Stewart to ... Tad have both played critical roles in building ...
... 9 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.,(NYSE Alternext US: ... in,China, announced today that the Chinese government, led ... the Ministry of Finance and the State,Administration of ... Co. Ltd.(Sinovac Beijing), high-tech enterprise status.,According to the ...
... BioStorage Technologies, Inc. (BST), a worldwide provider of long- ... chain logistics, announces the recent promotion of Lori Ball ... joined BioStorage Technologies in 2007 as Vice President of ... as well as corporate branding and domestic and international ...
Cached Biology Technology:Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development 2Sinovac Biotech Co. Ltd., Sinovac's Beijing Subsidiary, Obtains High-Tech Enterprise Status 2Sinovac Biotech Co. Ltd., Sinovac's Beijing Subsidiary, Obtains High-Tech Enterprise Status 3BioStorage Technologies, Inc. Promotes Lori Ball to Senior Vice President and Expands Role 2
(Date:11/6/2014)... a team of Florida State University biologists could lead ... to and survive environmental swings such as droughts or ... of the journal The Plant Cell , sheds ... proteins) is organized in a cell and how plants ... on and others are turned off. , "If you ...
(Date:11/5/2014)... in the UTSA College of Sciences, is one ... receive a two-year $300,00 National Science Foundation (NSF) ... funding supports President Obama,s BRAIN Initiative, a federal ... that will demystify complex brain processes. , ... broken into the interactions of multiple components, each ...
(Date:11/4/2014)... nature, the right amount of death at the right ... according to new research that could help in understanding ... stocks. , In a paper in the journal ... researcher and European colleagues conclude that the kind of ... loss of individuals, or mortality, depends on the size ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3When less is more: Death in moderation boosts population density in nature 2
... Researchers at the Swedish medical university Karolinska Institutet (KI) have ... parietal parts, to increase the understanding of the capacity of ... in the brain interact. One of the findings they have ... brain,s neuronal network that restricts the number of items we ...
... may one day help people who are not responding ... The Journal of Immunology . Scientists looking at ... to reduce the virus levels in the blood to ... called D-1mT alongside Anti-Retroviral Therapy (ART). Simian Immunodeficiency ...
... that its latest journal, Disease Models & Mechanisms ... MEDLINE. MEDLINE (http://www.pubmed.gov) is the premier bibliographic database of ... National Institutes of Health (NIH), MEDLINE contains over 16 million ... DMM has been recommended for inclusion by ...
Cached Biology News:Computer simulations explain the limitations of working memory 2Potential new HIV drug may help patients not responding to treatment 2Potential new HIV drug may help patients not responding to treatment 3Disease Models & Mechanisms -- selected for indexing in Medline 2
Rad 50 Immunogen: c-terminal mRad 50 (604 amino acids). Storage: 4 C...
...
... enhancements when used as directed, The ... designed to amplify the desired signal detected by Western ... with low expression., Membrane Enhancement Solution ... membrane; 1x solution; 250 ml, Membrane ...
Applications: Western blotting ...
Biology Products: